Report overview
Ursodeoxycholic acid is a bile acid used for the treatment of primary biliary cirrhosis (PBC), dissolution of radiolucent gallstones in patients with a functioning gallbladder, and treatment of hepatobiliary disorders associated with cystic fibrosis in pediatric patients.
This report aims to provide a comprehensive presentation of the global market for Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases. This report contains market size and forecasts of Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases in global, including the following market information:
Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases companies in 2022 (%)
The global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Capsule Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases include Dr. Falk Pharma, Daewoong Pharmaceutical, Teva, Humanwell, Mitsubishi Tanabe Pharma, Lannett, Mylan, Bruschettini and Impax, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Segment Percentages, by Type, 2022 (%)
Capsule
Tablet
Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Segment Percentages, by Application, 2022 (%)
Primary Biliary Cirrhosis(PBC)
Gallstones
Others
Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases revenues share in global market, 2022 (%)
Key companies Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Dr. Falk Pharma
Daewoong Pharmaceutical
Teva
Humanwell
Mitsubishi Tanabe Pharma
Lannett
Mylan
Bruschettini
Impax
Shanghai Pharma
Grindeks
Outline of Major Chapters:
Chapter 1: Introduces the definition of Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases, market overview.
Chapter 2: Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases market size in revenue and volume.
Chapter 3: Detailed analysis of Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
